Infectious Disease

Rituximab

Questions discussed in this category

Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?

Does your approach differ based on the underlying condition - such as ANCA-associated vasculitis, rheumatoid arthritis, or another autoimmune disease?

2 Answers available

In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?

5 Answers available

Do you utilize post-vaccination IgG titers to detect common variable immunodeficiency in patients who are about to start or are actively on B cell depleting therapy?

2 Answers available

Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?

1 Answer available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

Papers discussed in this category

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

Hepatology (Baltimore, Md.), 2018 Apr

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Gastroenterology, 2025 Feb

AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.

Lancet Haematol, 2018 Oct

Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.

Annals of the rheumatic diseases, 2018-05

Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question.

Infectious Disease

Rituximab

Questions discussed in this category

Papers discussed in this category

Related Topics in Infectious Disease